IFAPP Deplores Russia’s Aggression in Ukraine

The IFAPP Board and community are deeply shocked and unreservedly condemn the illegal and unprecedented invasion of Ukraine initiated by the government of the Russian Federation. IFAPP stands in solidarity with the people of Ukraine in these extraordinarily difficult times and appeals to Russia for an immediate end to hostilities. Our thoughts are with the Ukrainian people.

Furthermore, IFAPP Board expresses its profound concerns about Ukraine people healthcare and safety and support medical neutrality as declared by WMA. Ensuring safety and security of people is of utmost importance as well as access to medicines, vaccines and humanitarian aid to those who need them. Given that several clinical trials are currently operating in the regions of Ukraine, every effort should be made in order to serve patients and healthcare providers as much as possible.
Call for Candidates for IFAPP President-Elect

IFAPP is encouraging members of National Member Associations and Individual Affiliates to consider joining the IFAPP Board and becoming a candidate for the role of President–Elect. The election will take place at the House of Delegates meeting planned on the occasion of IFAPP's next International Conference on Pharmaceutical Medicine (ICPM 2022) in Athens, Greece, from 19 to 21 October 2022.

If you are interested, please send a Letter of Application to me as the Board Secretary outlining your reasons why you consider yourself qualified for this role, accompanied by your Curriculum Vitae. Please also provide a Letter of Recommendation from your National Member Association. As per IFAPP’s Constitution Individual Affiliates are also entitled to apply.

Applications must be received at least four weeks prior to the election date.

Anna Jurczynska, PhD, MBA
IFAPP Board Secretary
romanek.jurczynska@gmail.com

Chair of IFAPP Young Professionals Working Group (Standing Officer: Dr Annette Mollet, Switzerland)

After obtaining my master’s degree in Pharmacy from the University of Basel, I continued my education with a PhD in Neurobiology and Radiopharmacy at the Swiss Federal Institute of Technology in Zurich. Although I was very much fascinated about research, I wanted to work more at the end of the drug development process where you can see the implementation of new drugs and treatment options. I joined Roche and learned how to plan and perform phase 2 and 3 clinical studies, later the market introduction, and the conduct of phase 4 studies. During my time at Roche, I participated from 1995-1997 in the diploma course in Pharmaceutical Medicine at the University of Basel organised by ECPM, the European Center of Pharmaceutical Medicine.

Prof. Bühler who was the ECPM director at that time founded in 1995 the Swiss Association of Pharmaceutical Professionals - the first Swiss member of IFAPP. I had the great honour to be among the founding members of this society and served for 20 years on the board being responsible for continuing education and certification. We inaugurated in 1999 the specialist title for medical doctors and the SwAPP Diploma in Pharmaceutical Medicine for MSc, PhDs, etc. that combines theoretical knowledge with work experience.
In 1997, I joined ECPM and since then I have been contributing to training and research in Pharmaceutical Medicine. In 2009, a professorship was inaugurated which means that we became a university institute at the University of Basel teaching drug development science not only in the postgraduate but also in the undergraduate setting, and it is subject to our research interests. So far, we have been able to train more than 2,000 drug developers in the past 30 years. I very much enjoy the exchange and the support of our students to enhance their career.

To broaden my knowledge and expertise, I achieved an MBA in International Health Science in 2019. Since 2007, I have been chairing the Federal Expert Committee for the Evaluation of Radioactive Drugs, a joint committee of the Swiss Agency for Therapeutic Products (Swissmedic) and the Swiss Federal Office of Public Health (BAG), which allows me to experience the regulatory part.

From 2009-2014, ECPM was the coordinating centre of the PharmaTrain project, an Innovative Medicines Initiative (IMI) for training in Pharmaceutical Medicine, which is now continued within the PharmaTrain Federation after the closure of the EU project.

In 2020, I received the IFAPP Global Fellow in Medicines Development award and was elected chair of the new IFAPP Young Professionals Working Group in 2021.

Annette Mollet, PhD, MBA
Managing Director and Head Education and Training, ECPM, University of Basel, Switzerland

IFAPP Maintains Stable Membership Fees

As reported in our Aims & Objectives 2021-2023 the Board has reviewed the current membership fees based on various scenarios. The conclusion was that all scenarios were not helpful and had a direct negative impact on IFAPP’s annual revenues. Therefore, it has been decided that the current membership fees for National Member Associations (institutional fee of 150 EUR plus 4.50 EUR per individual NMA member and year, stable for over 15 years) and Individual Affiliates (30 EUR for Europe and 30 USD outside of Europe) will be kept.

Marco Romano MD PhD GFMD, IFAPP President

28 March 2022 - IFAPP House of Delegates Meeting
1:00-2:30 pm CET, 7:00-8:30 am EST, 8:00-9:30 pm JST
Dear Colleagues,

2022 is a special year. We celebrate the long-awaited return of the 20th ICPM since the last one in 2018. It will also be the first time that ICPM will be accessible both onsite and online, ensuring you have access to the very latest science and research updates, from wherever you are.

We will be delighted to welcome you to a live, interactive hybrid conference on what lies ahead in Pharmaceutical Medicine to meet, learn from and exchange with renowned academics, researchers, scientists, clinical investigators, regulators, health policy experts, bioethicists, R&D experts, Patient Advocates and Pharmaceutical Medicine Leaders.

Global R&D and New Technologies ecosystem special guests with Pharmaceutical Medicine experts will convene to discuss with invited executives from WMA, CIOMS, EUPATI, PharmaTrain, European Research Council, Swiss Clinical Trials Organisation, FPM and other international societies on current and emerging trends in biomedical research, precision medicine, advanced therapies, new technologies, evolving research governance, and contemporary ethical challenges.

EL.E.F.I. & IFAPP as co-hosts are warmly inviting you to an in-depth exploration of Pharmaceutical Medicine future through ICPM 2022 works and offer you exclusive access to discussions with experts, international networks as well as opportunities to connect with distinguished speakers, colleagues, and like-minded scientists.

Looking forward to seeing you in Athens for a unique learning journey and enlighten your professional perspective on what lies ahead in Pharmaceutical Medicine.

On behalf of the ICPM 2022 Organising Committee

Dr Varvara (Barbara) Baroutsou
Internist, GFMD, EMAUD
EL.E.F.I. President
IFAPP President Elect

Dr Marco Romano
MD, PhD, GFMD
IFAPP President
As the world's economic engine starts to rev-up and people’s movement becomes less restricted in terms of mobility-protection across destinations: work - home, we are still left with the challenge of people in the communities reluctant to accept vaccination against COVID-19. Understanding hesitancy of individuals in the communities to have themselves vaccinated is critical to maximising community immunity by convincing those not vaccinated to get vaccinated.

Based on a study done by Megan Gregory there are several themes that might have led to vaccine hesitancy (in the study the focus was on first responders – EMS):

- Level of trust with the government
- Mistrust in healthcare and medical sources
- Level of trust in social media
- Level of trust with employer and community
- Individual's decision to trust no one
- Individuals trust other options than vaccine
- Individuals express their right to practice autonomy (decide for themselves)
- Negative experience with the vaccine which sometimes results in low level of willingness to receive booster dose

A major theme is mistrust due to COVID-19 messaging that has evolved over time. Changing messages seem to have led to various levels of erosions of trust in institutions indicating that leadership in a public health crisis needs to send messages that are consistent and accurately communicate potential uncertainties. Although it is also clear that trust alone is not the only deciding factor for having the vaccination. Other reasons why people do decide to have vaccination despite having trust concerns was the belief that it could protect once self and others. The decision came from perceived risks of COVID-19.
Vaccine hesitancy exists along a continuum from those who are strongly opposed to be vaccinated to those who felt strongly poised to be vaccinated if they would receive more reassurance about safety and efficacy. The continuum suggests attention should be the focus to increasing vaccine uptake by providing reassurance and facts to majority of vaccine-hesitant individuals who are still persuadable.

In an article by Angela K. Shen, they introduce the conceptual approach ASPIRE:

- Assume that people want to get vaccinated and be prepared for questions
- Share key facts and sources of information to counter misinformation
- Present strong recommendations to be vaccinated and stories about vaccination experiences
- Initiate discussions or address questions about adverse effects proactively and share sources of information
- Respond to questions and actively listen
- Emphasize and understand concerns

Vaccine hesitancy remains a public health concern. A challenge that we need to take on and face in this New Normal. The Future is on your hands!

Rodelio C. Bito, MD
Associate Medical Director
PSSR- Pfizer Inc. (Philippines)

References:


EUPATI Celebrates its 10th Anniversary

Improving health outcomes since 2012

The European Patients’ Academy on Therapeutic Innovation (EUPATI) is committed to improving health outcomes through the contribution from patients and patient representatives as valued stakeholders in the medicines R&D process.

EUPATI provides accessible, innovative, and inclusive education empowering patients and patient representatives with the right knowledge, skills, and competencies to effectively engage and partner with all other stakeholders.

EUPATI was launched on 01 February 2012 as a project funded by the Innovative Medicines Initiative (IMI) that would last until 2017. The European Patients’ Forum (EPF) further hosted the project until EUPATI was established as a foundation in the summer of 2020.
EUPATI success story in 10 key achievements:

1. **5 million unique users of the Toolbox.**
The Toolbox is a free-to-use online resource available in 13 languages. The content of the toolbox is constantly improving and updated. Users can find articles, infographics, webinars, etc. on the following subjects:

   - Basics of Medicines R&D
   - Clinical Development / Trials
   - Drug Discovery
   - Personalised Medicine
   - Regulatory Affairs
   - Pharmacoepidemiology
   - Benefit and Risk Assessment
   - HTA
   - Pharmaceutical Development
   - Safety of Medicines
   - Non-Clinical Studies
   - Types of Medicines

Access to the Toolbox: https://toolbox.eupati.eu/

2. **Creation of the Open Classroom**
The EUPATI Open Classroom was launched in 2020, as a new format of the EUPATI Patient Expert Training Programme. The EUPATI Open Classroom is a flexible, on-demand e-learning platform allowing more patients, patient representatives and other stakeholders from anywhere in the world to access expert-level training in medicines research and development (R&D). Accessible learning modules follow the EUPATI Patient Engagement Roadmap and take the learner through non-clinical and clinical development to regulatory affairs and HTA processes. The EUPATI Open Classroom was supported by the EUPATI Reload project, funded by EIT Health. There are already over 400 Open Classroom learners who have registered since the launch.

Access to the Open Classroom here: https://learning.eupati.eu/

3. **A growing community of EUPATI Fellows**
Each year EUPATI welcomes a new cohort of trainees who can become EUPATI Fellows if they complete all the Open Classroom learning modules and attend two training events. EUPATI Fellow is today a widely well-known label within the patient engagement landscape, and they are highly sought-after partners by different stakeholders. As of 2021, more than 200 Fellows have graduated from the programme, coming from over 30 countries.

4. **International network of EUPATI National Platforms**
Since 2012 EUPATI has developed a network of 23 National Platforms established in 23 countries. National Platforms gather patients, academia and industry representatives to raise awareness of patient education and patient involvement in medicines R&D nationally. They operate independently but are driven by EUPATI’s vision and mission.

Learn more about the National Platforms: https://eupati.eu/national-platforms/
5. Successful partnerships
EUPATI works closely with its 36 partners representing patient organisations, not-for-profit and academic institutions, and pharmaceutical industry. This public-private partnership gives a unique approach to EUPATI's mission to support meaningful patient engagement through education.

Early 2022 EUPATI launched a new platform connecting EUPATI Patient Experts (EUPATI Fellows and EUPATI Open Classroom learners) with researchers looking to involve patients in various projects (e.g., protocol reviews, focus groups, speaking opportunities, patient advisory boards, ethics committees or regulatory processes). EUPATI Connect is a place where both EUPATI Patient Experts and researchers can build new connections, create synergies and mutually beneficial opportunities to enhance patient engagement. Access to EUPATI Connect: https://connect.eupati.eu/

7. Training of stakeholders
Since 2019, EUPATI has provided training on patient engagement to professionals from academia and industry. These trainings are co-created and co-delivered by patients, structured around problem-based learning, and based on real-life examples. To date, more than 500 individuals have benefited from these trainings and new modules are under development.

8. Cross-stakeholder collaborations
In addition to its Sustaining Partners, EUPATI collaborates with a wide range of stakeholders within the patient education and patient engagement landscape. EUPATI engages in close collaboration with e.g., Innovative Health Initiative (IHI) Patient Focused Medicines Development (PFMD), EMA and national regulatory agencies, Health Technology Assessment international (HTAi) and several other organisations.

9. Establishing governance as an independent foundation
EUPATI functions today as an independent, non-profit organisation in the Netherlands. Its governance structure reflects the spirit of a true public-private partnership and has representatives of patient organisations, non-profit/academic institutions, industry, regulators and HTA in its decision-making bodies.

10. International Virtual Secretariat
The EUPATI Team is led by the Executive Director and currently consists of 10 individuals from various backgrounds and countries. The EUPATI Secretariat benefits from this diversity in its commitment to enhance patient education and patient involvement.

“EUPATI is a true success story demonstrating the strength of multi-stakeholder collaboration driven by a shared objective. The establishment of EUPATI as a non-profit independent foundation was a key milestone in our 10-year journey and it would not have been possible without the substantial contributions of our partners and wide networks of the EUPATI Fellows and National Platforms. We will continue to expand our activities, building on our shared vision and mission, to enhance patient engagement through education in Europe and beyond.” Maria Dutarte, EUPATI Executive Director
Celebration in Brussels
EUPATI will gather key actors and partners next May in Brussels to celebrate its 10th anniversary. More information to come on EUPATI's website: https://eupati.eu/ and social media.

Coline Guiol (Communication and EUPATI National Platforms (ENP) Network Coordinator) & Maria Dutarte (Executive Director), EUPATI Foundation, Utrecht, The Netherlands

Report of the Asian Regional Meeting - What's up for the Asian NMAs?

The most recent Asian Regional Meeting took place on 30 October 2021 and was held as part of the annual congress of JAPhMed, IFAPP's Japanese member association.

Venue: Zoom meeting
Date: 30 October 2021 (Sat), at 12:40-13:40 (Tokyo time)

Agenda:
1) Introduction of the new IFAPP Board of Officers and IFAPP in general
2) Materials available for national member associations (NMAs): e.g., IFAPP TODAY, webinars on the COVID-19 situation in various countries
3) Expectations from Asia regarding IFAPP working group activities (participants from Asian NMAs/Individual Affiliates)
4) Discussion
5) Any other proposals for discussion

The participants were:
Ajay Tiku: Singapore (first row, first from the right)
Chinnie Tan (second row, first from the left), Maria Pamela Chua, Rodelio Bito (second row, middle), Jonas D Policarpio: Philippines
Kyoko Imamura, Kotone Matsuyama: Japan (first row, first and second from the left)
Through the discussion, we found the common interests of Asian NMAs.

1) Young professionals: Mentoring is considered as a common agenda
2) Education & Certification: Current overseas programmes are good but not affordable for self-financing trainees. Opportunities are appreciated before getting the job, but further development should be considered once started their professional lives. One possibility is to collaborate with PharmaTrain. In Asian countries, there are not so many specialised personnel, so that we should construct some kind of mentoring programme such as the SMD (Specialist in Medicines Development) programme and also should ask integrated efforts in mentoring in workplaces on top of basic knowledge education.

Based on these interests, we are preparing the roundtable session at the upcoming ICPM titled "Asian expectations of new education and training for all in Pharmaceutical Medicine."

We are also planning a pre-ICPM session to discuss related topics such as "The Medical Affairs (MA) role in APPA (Australian Pharmaceutical medical and scientific Professionals Association, draft)" on 28 July 2022, as a part of the JAPhMed annual congress.

We agreed that we need education and certification for Medical Affairs professionals (not only Medical Science Liaisons (MSLs) but also Medical Directors, for example), and capability frameworks should be established to develop well qualified MA professionals with certification accredited by established authorities. Our APPA colleagues can also guide us on basics of Health Technology Assessment (HTA), upon which we can adapt to national healthcare systems to make our products accountable for the society. They can also introduce us to MAPS, the Medical Affairs Professional Society.

Please try to participate in the upcoming Asian Regional Meetings.

Kotone Matsuyama
Professor, Department of Health Policy and Management,
Deputy Director, Center for Strategic Research Initiative, Nippon Medical School
Director, Board Certified Member of JAPhMed
IFAPP Standing Officer and Chair of the Ethics Working Group

New CIOMS Working Group on Principles of Good Governance for Research Institutions (PGGRI)

The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organisation established jointly by WHO and UNESCO in 1949 (1). Their mission is to advance public health through guidance on health research including ethics, medical product development and safety. In the bioethics area, one of the remarkable works of CIOMS is the continued publication on ethical guidelines and the latest one entitled "International Ethical Guidelines for Health-related Research Involving Humans" prepared in collaboration with WHO, published in 2016 (2).
In 2018, IFAPP, the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine, joined CIOMS. On behalf of the IFAPP Ethics Working Group (WG), I have joined the newly established CIOMS working group named “Working Group on Principles of Good Governance for Research Institutions (GGPRI)” last October. According to this WG background, the World Medical Association (WMA) included a section on governance in the Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks in 2016. This demonstrates the need for a different approach to research ethics that addresses the responsibilities of the institutions in which researchers are working. The main objective of this WG is to propose standard guidelines promoting the minimal resources needed for researchers to work in accordance with the highest standards in research ethics and regulation (3).

CIOMS Working Groups usually take 2-4 years to finalise their consensus document and recommendations. The first meeting was held in July 2021, and so far, the WG members are divided into 4 sub-groups to build up the draft guiding document, including an introduction, glossary, and checklist of all recommendations. The draft document will set a public consultation. Based on that public consultation, the document should be finalised and published. Considering the experience with the COVID-19 pandemic, it is clear that governance in research institutions has a major impact on all aspects of research, and I feel that the social significance of producing the outputs from this WG is extremely high. We will do our best to ensure that the fruits of these guidelines will be of significance.

1) https://cioms.ch/about/
2) https://cioms.ch/product/international-ethical-guidelines-for-health-related-research-involving-humans/
3) https://cioms.ch/working_groups/principles-of-good-governance-for-research-institutions/

Kotone Matsuyama
Professor, Department of Health Policy and Management,
Deputy Director, Center for Strategic Research Initiative, Nippon Medical School
Director, Board Certified Member of JAPhMed
IFAPP Standing Officer and Chair of the Ethics Working Group
Competence is the combination of knowledge, skills and attitude. In the professional development of physicians, the worldwide approach consists of a comprehensive academic education with fostering of the newly acquired knowledge in mentored daily practice over several years, leading to a certification in an achieved specialisation, based on a final assessment of the physician’s competencies. Due to national differences in need of identification and based on resistance from the national physician chambers towards the establishment of Pharmaceutical Medicine as a medical discipline, postgraduate education in Pharmaceutical Medicine developed in different steps and speed in different countries. Universities were mostly not interested as postgraduate diploma or master courses did not fit into their standard bachelor and master graduation schemes.

Nevertheless, post-graduate diploma and master courses in Pharmaceutical Medicine for both physicians and scientists involved in the development of medicines were established in various countries like UK, Ireland, France, Italy, Germany, Switzerland, Belgium, Sweden, Brazil, and later in Portugal, Japan, etc. Many of the course providers were members of IFAPP or involved with IFAPP. In the early years of the new century, two interesting developments occurred in parallel: the growing need for alignment and harmonisation of education content and teaching standards was addressed in 2008 by the foundation of EFCPM, the European Federation of Courses in Pharmaceutical Medicine, in Basel, Switzerland, driven by a core team of European course providers, led by Prof Fritz Bühler, ECPM, and Prof Gerfried Nell, IFAPP.

The first activity of EFCPM was the formation of the EFCPM Training Network Partnership in 2009 together with IFAPP and the Faculty of Pharmaceutical Medicine, UK. In parallel, the European Commission, Directorate Research and Innovation, and EFPIA, the European Federation of Pharmaceutical Industries and Associations, developed the strategy for a huge public-private partnership called “IMI” (Innovative Medicines Initiative) to boost the availability of new treatments through collaboration between industry and academia in pre-competitive topics. EFCPM and IFAPP successfully raised awareness for the fact that more efficient medicines development would not only require experts in specific areas of science and technology but also experts with competence in understanding the overall challenges in the development of new types of medicines and vaccines, able to drive new development strategies over the whole life cycle of a medicine. Such expertise would require top quality, comprehensive education and competence development in Pharmaceutical Medicine for all stakeholders involved.

![Bottlenecks R&D Process](image)

**Figure 1:** IMI strategy to overcome the bottleneck in the R&D process
As a result, a call for building and implementing an education framework for Pharmaceutical Medicine was released by IMI in 2009. A consortium consisting of EFCPM, IFAPP, a large number of universities, and not-for-profit organisations active in Pharmaceutical Medicine education submitted an Expression of Interest and were invited to submit a Full Project Proposal together with leading pharmaceutical companies. The proposed project was called "PharmaTrain" and was selected. In fact, this was the very first IMI project that started. The consortium was successful in engaging the course providers, IFAPP, and the pharmaceutical companies to jointly develop a syllabus for post-graduate Pharmaceutical Medicine education, now called the "PharmaTrain Syllabus", updated and jointly released by PharmaTrain, IFAPP, and the Faculty of Pharmaceutical Medicine, UK. As most suitable teaching methodology, reflecting the local and time flexibility needs of students working in industry or academia, a modular curriculum approach for diploma and master programmes was agreed.

As a pre-requisite for mutual recognition of modules by collaborating universities and for reliable teaching standards a quality framework for course providers was developed and described in a comprehensive Handbook. To ensure adherence to this agreed quality standard a PharmaTrain course recognition system was established, independent from national accreditation systems. In a comprehensive onsite and remote review process by three independent assessors the successful demonstration of reliable adherence to these quality standards in diploma or master courses in Pharmaceutical Medicine leads to the recognition of being a “PharmaTrain Centre of Excellence”.

Diploma and master courses in related disciplines like safety, pharmacovigilance, regulatory affairs, etc. can achieve the recognition as a “PharmaTrain Centre”. Re-assessment is due after three years.

The third big achievement was the joint establishment of a concept and framework for a vocational certification programme in Pharmaceutical Medicine for physicians and in medicines development for non-physicians: Candidates who had successfully completed a PharmaTrain-recognised diploma or master course in Pharmaceutical Medicine and who applied their acquired knowledge in a 3- to 4-year long mentored on-the-job rotation programme can achieve the certification as a globally recognised “Specialist in Medicines Development (SMD)”. The IMI follow-on project "IMI-TRAIN" (see below) enabled PharmaTrain to run an SMD pilot project in Italy and Japan.

Additional standard setting activities within the PharmaTrain project included the development of a standard syllabus and curriculum for clinical investigator training (“CLIC”) from basic to sponsor-investigator levels and a syllabus and curriculum for master courses in regulatory affairs.

A crucial success factor for IMI projects is the establishment of a sustainability strategy for the time after the end of the IMI project. For this purpose, EFCPM was transferred 2012 into the not-for-profit organisation “PharmaTrain Federation”, established in Basel, Switzerland, where IFAPP was again a founding member.
After the end of the IMI PharmaTrain project IMI released a follow-up call for the first IMI projects that then had come to an end if they fulfilled the prerequisite of agreement from all original consortium members to make all outcomes of the original project publicly available which was the case for PharmaTrain. In the area of educational calls, the second requirement was the formation of a joint consortium of all former IMI education projects: PharmaTrain, EMTRAIN, EU2P and Safe-Sci-Med. This collaboration was achieved and thus two further years were funded by IMI to jointly work towards a European educational framework in medicines development.

At the time of proposal submission for this follow-on project in 2014 it was not clear whether Switzerland would continue to be able to participate in EU-funded projects due to ongoing disputes about an EU-Switzerland collaboration agreement. To avoid any potential difficulties for funding in the IMI follow-on project, IMI recommended PharmaTrain Federation to move the legal seat of the organisation into an EU country. Thus, PharmaTrain Federation asbl was founded in Brussels, Belgium, in 2014. Today, PharmaTrain Federation continues to focus on course recognition and re-assessments, works with IFAPP and the Faculty of Pharmaceutical Medicine, UK, on further improvements of the PharmaTrain Syllabus, and broadens the options for SMD programmes in different countries.

From its constitution until today, the PharmaTrain Federation continues to work very closely with IFAPP: IFAPP is not only represented in the PharmaTrain Federation Board but the IFAPP delegate is a member of the Executive Board and one of the two Vice Presidents, thus a legally responsible Director of the PharmaTrain Federation. After Gerfried Nell and Sandor Kerpel-Fronius, Brigitte Franke-Bray has been elected into this position at the PharmaTrain Federation General Assembly in February 2022.

Ongoing close collaboration with the PharmaTrain Federation is an important element of the IFAPP strategy for education and training in Pharmaceutical Medicine as this independent recognition of quality-minded course providers, the agreed standards and content of teaching in Pharmaceutical Medicine and the options for broadly establishing a globally recognised Pharmaceutical Medicine specialisation programme are crucial stepping stones for global, formal recognition of Pharmaceutical Medicine as a mandatory contributor to efficient development of new medicines for our patients.

Ingrid Klingmann, MD, PhD, FFPM, FBCPM, GFMD  
President PharmaTrain Federation asbl
Kotone Matsuyama Newly Elected Member of CIOMS and IRDiRC Working Groups

The IFAPP Board wishes to congratulate Professor Kotone Matsuyama, GFMD, Nippon Medical School, Japan, Chair of IFAPP’s Ethics Working Group, for having been elected recently into:

- the CIOMS* Working Group on Principles and Good Governance for Research Institutions (PGGRI; please read also Kotone Matsuyama’s contribution on pages 10 and 11)

- the MedTech Working Group of IRDiRC, the International Rare Diseases Research Consortium, an organisation that provides focus with a wide range of rare diseases such as sharing of standardised data and samples, molecular and clinical analysis of rare diseases, bridging research from non-clinical to clinical trials, and simplification of ethical and regulatory procedures. This Working Group will primarily focus on devices used for either the treatment of rare diseases, such as implants, and devices used to support physical activities of patients, such as exoskeletons.

*CIOMS: Council for International Organizations of Medical Sciences